This publication explores the role of community engagement in health-related research and development (R&D), particularly within the Unitaid-funded LONGEVITY Project. LONGEVITY, led by the University of Liverpool and whose consortium members include Treatment Action Group, aims to develop long-acting technologies (LATs) to prevent tuberculosis (TB) and to cure hepatitis C virus (HCV).

To ensure that any eventual LATs benefit the communities that need them, TAG and Afrocab created the Long-Acting Technologies Community Advisory Board (LAT CAB,) a network of research literate survivors, civil society members, clinicians, and activists who advocate for affected community priorities at every step of the R&D, implementation, and policymaking process. To illustrate LAT CAB’s key role, we’ve included excerpts from their communications with various global health actors.